Drug
Glucagon clinical trials
Also written LY900018, GlucaGen, AMG504-1 and Baqsimi.
Includes 1 study of Glucagon hydrochloride.
- studies test it
- 79
- open now
- 5
- in phase 3
- 14
- first study started
- 2002
Keep track of what changes. Save the Glucagon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Glucagon
- 50
Combined with it in one product
Studies by the year they started
77 studies that test it; most in 2017 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 9 |
| 2018 | 8 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 22
- Phase 2
- 18
- Phase 3
- 14
- Phase 4
- 12
- No phase
- 16
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 49
Eli Lilly and Company (12) · Xeris Pharmaceuticals (9) · Steno Diabetes Center Copenhagen (6) · Institut de Recherches Cliniques de Montreal (4) · Joslin Diabetes Center (3) · University Health Network, Toronto (3) · Legacy Health System (3) · AdventHealth Translational Research Institute (2)
Often tested with
Tested in the same studies.
Glucose (4) · Somatostatin (2) · Insulin, Regular, Human (2) · Octreotide (2) · Human Growth Hormone (2) · Insulin (2) · Exenatide (1) · Dasiglucagon (1)
Studies
Open first, then newest update. How each study uses Glucagon is read from its arms, and is right about nine times in ten.
Testing it · 79
- Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)RecruitingPhase 4Joslin Diabetes CenterNCT07818707Written as Glucagon for Injection (Fresenius Kabi USA)
- The Postprandial Hypo-Avoid StudyRecruitingPhase 4Steno Diabetes Center CopenhagenNCT07427251Written as Low-Dose Glucagon
- Studies of Insulin and Glucagon Action in the LiverNot yet recruitingPhase 1/2Duke UniversityNCT07300982Written as Glucagon
- Human Models of Selective Insulin Resistance: Pancreatic ClampNot yet recruitingPhase 1Columbia UniversityNCT06558422Written as Glucagon
- The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.Not yet recruitingNot applicableBispebjerg HospitalNCT06872060Written as Glucagon
- The Effects of Glucagon on Hepatic MetabolismCompletedPhase 1/2Adrian VellaNCT05500586Written as Glucagon response study
- To Determine Tolerability to Glucagon Infusion in Obese SubjectsActive, not recruitingPhase 1AdventHealth Translational Research InstituteNCT02817659Written as Glucagon
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese SubjectsActive, not recruitingPhase 1AdventHealth Translational Research InstituteNCT03139305Written as Glucagon
- Glucagon Dose-Response in Patients With Post-Bariatric HypoglycemiaActive, not recruitingPhase 4Joslin Diabetes CenterNCT06986603Written as Glucagon for Injection (Fresenius Kabi USA)
- Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETActive, not recruitingNot applicableRigshospitalet, DenmarkNCT07366710Written as Glucagon
- Pancreatic Clamp in NAFLDCompletedPhase 1Columbia UniversityNCT05724134Written as Glucagon
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsCompletedPhase 1Novo Nordisk A/SNCT06588504Written as Glucagon
- Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT05379686Written as GlucaGen
- Glucagon Use in ColonoscopiesCompletedPhase 4University of California, San FranciscoNCT02078726Written as Glucagon
- Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1TerminatedPhase 2St. Olavs HospitalNCT05960565Written as Glucagon
- The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTACompletedPhase 1Yale UniversityNCT03965130Written as Glucagon
- Effect of Physiologic Hyperglucogonemia on Adipocyte MetabolismCompletedEarly Phase 1The University of Texas Health Science Center at San AntonioNCT04300049Written as Glucagon Infusion
- A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT04992312Written as Glucagon Nasal Powder [Baqsimi]
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersCompletedNot applicableCambridge University Hospitals NHS Foundation TrustNCT03835013Written as Glucagon (25ng/kg/min)
- Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT05076292Written as GlucaGen
See all 79 studies that test Glucagon →
Given in every arm · 12 — Glucagon is usual care beside what is tested
- Liver Glycogen and Hypoglycemia in HumansActive, not recruitingPhase 1Jason WinnickNCT03241706Written as Glucagon
- Dexamethasone/Pancreatic Clamp P&FWithdrawnPhase 1Columbia UniversityNCT06126354Written as Glucagon
- Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 DiabetesStatus unknownNot applicableNordsjaellands HospitalNCT05095259Written as Glucagon
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusCompletedPhase 1SanofiNCT02910518Written as Glucagon
- Feasibility Trial Testing the Bionic Pancreas With ZP4207CompletedPhase 2Zealand PharmaNCT02971228Written as Glucagon
- A Study of Nasal Glucagon in Participants With a Common ColdCompletedPhase 1Eli Lilly and CompanyNCT02778100Written as Nasal Glucagon
- Study of LY2409021 in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01640834Written as Glucagon
- Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of GlucagonCompletedPhase 4Massachusetts General HospitalNCT02516150Written as Glucagon
- Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2CompletedPhase 2Institut de Recherches Cliniques de MontrealNCT02798250Written as Glucagon
- Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop OperationCompletedPhase 2Institut de Recherches Cliniques de MontrealNCT02626936Written as Glucagon
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT02012166Written as Glucagon
- Effect of LY2189265 on Insulin Secretion in Response to Intravenous GlucoseCompletedPhase 1Eli Lilly and CompanyNCT01300260Written as Glucagon
As the comparator · 11 — what is tested is compared with Glucagon
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop SystemWithdrawnPhase 2Inreda Diabetic B.V.NCT05454709Written as GlucaGen
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedPhase 3Zealand PharmaNCT03667053Written as GlucaGen HypoKit
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedPhase 3Zealand PharmaNCT03378635Written as GlucaGen
- First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.CompletedPhase 1Novo Nordisk A/SNCT03444467Written as Glucagon
- A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DMCompletedPhase 1AdociaNCT03176524Written as GlucaGen® HypoKit®
- ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02916251Written as Glucagon (Native glucagon)
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy VolunteersCompletedPhase 1Hospira, now a wholly owned subsidiary of PfizerNCT00745186Written as Glucagen
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced HypoglycemiaWithdrawnPhase 1SanofiNCT02635243Written as r-glucagon
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus PatientsCompletedPhase 1SanofiNCT02625636Written as r-glucagon
- Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02660008Written as GlucaGen
- Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorCompletedPhase 1Zealand PharmaNCT02367053Written as Glucagon
Codes
What other systems call Glucagon · ClinicalTrials.gg INT007556
- MeSH (NLM) D005934GlucagonOne source ClinicalTrials.gov
- UNII (FDA) 76LA80IG2GGLUCAGONOne source FDA
- RxNorm 4832One source FDA
- NCI Thesaurus C520Recombinant GlucagonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005934 | Glucagon | One source ClinicalTrials.gov |
| UNII (FDA) | 76LA80IG2G | GLUCAGON | One source FDA |
| RxNorm | 4832 | — | One source FDA |
| NCI Thesaurus | C520 | Recombinant Glucagon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.